



TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)

Madrid, 17 June 2026

In compliance with the information duties provided for in article 227 of the Law 6/2023, of 17 March, on the Securities Markets and Investment Services, Laboratorios Farmacéuticos Rovi, S.A. (hereinafter, the “**Company**”) hereby discloses to the Spanish National Securities Market Commission the following

OTHER RELEVANT INFORMATION

The Ordinary General Shareholders’ Meeting held today, 17 June 2026, on first call, has approved all the proposed resolutions submitted by the Board of Directors to its approval and summarized as follows:

1. Approval of the individual financial statements of the Company and of the consolidated financial statements of the Company with its subsidiaries, as well as of the individual management report of the Company and the consolidated management report of the Company with its subsidiaries, all for the financial year ended 31 December 2025.
2. Approval of the statement of non-financial information and sustainability information included in the consolidated management report of the Company with its subsidiaries for the year ended 31 December 2025.
3. Approval of the proposal for the application of the individual profit for the year ended 31 December 2025, including the distribution of a supplementary dividend, for a total combined amount of 0.9594 euros gross per share entitled to receive it. The abovementioned amount will be paid on 15 July 2026.
4. Approval of the management work and performance of the Board of Directors during the year ended 31 December 2025.

5. Approval of the re-election of Ms. Marina del Corral Téllez as a proprietary external director, for the statutory period.
6. Approval of the maximum annual remuneration of the members of the Board of Directors in their capacity as such for the 2026 financial year.
7. Re-election of KPMG Auditores, S.L. as auditors of the Company and its consolidated group for financial year 2026, and financial years 2027-2029.
8. Delegation of powers to formalise and register the resolutions adopted by the General Shareholders' Meeting and to carry out the mandatory filing of the financial statements.
9. Approval of the annual report on Directors' remuneration with an advisory vote.

The text of the resolutions approved by the General Shareholders Meeting and the outcome of the voting will be published on the Company's website within the next five days.

Mr. Juan López-Belmonte Encina

Chairman of the Board of Directors and Chief Executive Officer (*Consejero Delegado*)
Laboratorios Farmacéuticos Rovi, S.A.